| Literature DB >> 22389661 |
Beate Strehlitz1, Christine Reinemann, Soeren Linkorn, Regina Stoltenburg.
Abstract
Aptamers are single-stranded DNA or RNA oligonucleotides, which are able to bind with high affinity and specificity to their target. This property is used for a multitude of applications, for instance as molecular recognition elements in biosensors and other assays. Biosensor application of aptamers offers the possibility for fast and easy detection of environmental relevant substances. Pharmaceutical residues, deriving from human or animal medical treatment, are found in surface, ground, and drinking water. At least the whole range of frequently administered drugs can be detected in noticeable concentrations. Biosensors and assays based on aptamers as specific recognition elements are very convenient for this application because aptamer development is possible for toxic targets. Commonly used biological receptors for biosensors like enzymes or antibodies are mostly unavailable for the detection of pharmaceuticals. This review describes the research activities of aptamer and sensor developments for pharmaceutical detection, with focus on environmental applications.Entities:
Year: 2011 PMID: 22389661 PMCID: PMC3281204 DOI: 10.1007/s12566-011-0026-1
Source DB: PubMed Journal: Bioanal Rev ISSN: 1867-2094
Examples of aptamers selected for pharmaceuticals
Examples of aptamer-based biosensors and assays for pharmaceutical detection
| Target/measurement of | DNA/RNA aptamer | Ref of aptamer description | Transducer/assay | Limit of detection | Linear range (μM) | Ref of sensor/assay |
|---|---|---|---|---|---|---|
| Oxytetracycline | DNA | [ | ec, chip system, labeled | 0.005–0.1 | [ | |
| Tetracycline | DNA | [ | ec, screen-printed electrode, CV, SWV, label-free | 10 nM | 0.01–10 | [ |
| Neomycin | RNA | [ | ec, competitive impedimetric, label-free | 0.75–500 | [ | |
| Tobramycin | RNA | [ | ec, competitive impedimetric, label-free | ATA 0.7 μM | ATA 1.4–70 | [ |
| FATA 0.4 μM | FATA 0.8–34.9 | |||||
| Aminoglycoside | RNA | [ | ec, labeled | 2–6 | [ | |
| Cocaine | DNA | [ | Optical, colorimetric, labeled | 50–500 | [ | |
| Cocaine | DNA | [ | Optical, FRET, labeled | 10–4,000 in blood serum | [ | |
| Cocaine | DNA | [ | Optical, colorimetric dipstick | 10 μM | [ | |
| Cocaine | DNA | [ | ec, microfluidic, labeled | 10–100 in blood serum | [ | |
| Cocaine | DNA | [ | Optical, FRET, labeled | 10 μM | 10–1,000 | This publication |
| Cocaine | DNA | [ | Optical, FRET, labeled | 10–1,250 | [ | |
| Cocaine | DNA | [ | Optical, FRET, labeled | 1 μM | 1–1,000 | [ |
| Optical, excimer fluorescence, labeled | 100 μM | 100–1,000 | ||||
| ec, LSV, labeled | 10 μM | 10–1,000 | ||||
| Cocaine | DNA | [ | ec, CV, labeled | <10 μM | [ | |
| Cocaine | DNA | [ | ec, pulse voltammetry, label-free | 0.1 μM | 0.1–38.3 | [ |
| Cocaine | DNA | [ | ec, chronocoulometric, label-free | 70 nM | 0.1–26.3 | [ |
| Cocaine | DNA | [ | Optical, colorimetric, labeled | 50 nM | 0.1–20 | [ |
| Cocaine | DNA | [ | Electrogenerated chemiluminescence, labeled | 1 nM | 0.005–0.3 | [ |
| Cocaine | DNA | [ | Optical, fluorescence, rolling circle amplification, labeled | 0.48 nM | 0.001–0.05 | [ |
| Cocaine | DNA | [ | Electrogenerated chemiluminescence, labeled | 10 pM | [ | |
| Vasopressin |
| [ | Optical, SERS, label-free | 5.2 μU/ml | [ | |
| Dopamine | RNA | [ | Optical, colorimetric, ELAA, labeled | 1 pM | 0.00005–0.1 | [ |
| 17β-Estradiol | DNA | [ | ec, CV, SWV, label-free | 0.00001–0.001 | [ |
CV cyclic voltammetry, ec electrochemical, ELAA enzyme-linked aptamer-based assay, FRET fluorescence resonance energy transfer, LSV linear sweep voltammetry, SERS surface-enhanced Raman spectroscopy, SWV square wave voltammetry
Sequences of the cocaine aptamer (original [79–81] and modified [152]) and quencher oligonucleotide [152] used for a cocaine assay with FRET-based detection
| Anti-cocaine aptamer (original [ | 5′-GGGAGACAAGGATAAATCCTTCAATGAAGTGGGTCGACA-3′ | 39 nt |
| Modified anti-cocaine aptamer | 5′-Fl– | 44 nt |
| + | ||
| Complementary quencher oligo | 5′-GTCTCCC | 12 nt |
The functionality of the assay is depicted in Fig. 1. Letters in bold are added nucleotides, letters in italic are replaced nucleotides, and underlined are complementary sequence parts of the aptamer
Fl Fluorescein marker, D Dabcyl marker
Fig. 1Functionality of a FRET-based cocaine assay by use of the modified cocaine aptamer and a quencher oligonucleotide [152]. In the absence of cocaine, the quencher oligomer is able to hybridize to the partially unfolded aptamer. Fluorophore and quencher come into close proximity and fluorescence is deleted. The fluorescence in the measuring solution reaches a minimum. In the presence of cocaine, the aptamer folds in the typical three-way junction forming a stable aptamer-binding complex. The quencher oligomer is displaced from the aptamer and released into the surrounding solution. Fluorophore and quencher are now far away from each other. The fluorescence intensity increases in dependence of the cocaine concentration in the measuring solution
Fig. 2Measuring curve for cocaine detection by measurement of fluorescence change in the aptamer-based cocaine assay (Fig. 1), c [cocaine] = 0–5 mM [152]. The saturation curve was used for the determination of K D = 134.4 ± 7.2 μM by non-linear regression analysis